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ABSTRACT
Hydroxyapatite (HA) used for bone replacement is one of the most active areas of ceramic biomaterials research currently. 
It has been used clinically for the last 20 years due to its excellent biocompatibility, osseoconduction and osseointegration. 
Many modifications have been done to develop a stronger, tougher and biocompatible ceramic biomaterial because 
pure HA is brittle. Researchers in Universiti Sains Malaysia had developed this value added HA that is stronger and less 
brittle compared to pure HA. The objective of this in vitro study was to evaluate the genotoxic characteristic of the value 
added HA based material by using Bacterial Reverse Mutation Assay (Ames test). The Bacterial Reverse Mutation Assay 
of HA was performed on Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and Escherichia coli strain 
WP2 uvrA using the preincubation method in the presence and absence of an exogenous metabolic activation system. 
All the bacterial tester strains treated with and without S9 Mix showed no increase of revertant colonies with increase 
in concentration of test substance for both the dose finding test and the main test. The number of revertant colonies was 
less than twice that of the solvent control for all the five bacterial strains and this was reproducible for both the dose 
finding test and the main test. The numbers of revertant colonies in the negative and positive controls were within the 
background data of our laboratory. In conclusion the results of the tests showed that the value added HA was considered 
to have no reverse mutagenic potential under the present test conditions.
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ABSTRAK
Hidroksiapatit (HA) yang digunakan untuk tulang gantian merupakan salah satu daripada bidang penyelidikan biobahan 
seramik yang paling aktif masa kini. Ia diguna secara klinikal sejak 20 tahun dahulu disebabkan oleh sifatnya yang 
sangat baik daripada sudut bioserasi, oseokonduksi dan oseointegrasi. Banyak pengubahsuaian telah dilakukan untuk 
menghasilkan biobahan seramik yang lebih kuat, lebih keras dan bioserasi disebabkan HA yang asli adalah rapuh. 
Penyelidik Universiti Sains Malaysia telahpun menghasilkan HA tambah nilai ini yang lebih kuat dan kurang rapuh 
berbanding dengan HA asli. Tujuan kajian in vitro ini adalah untuk menilai sifat genotoksik bahan berdasarkan HA 
tambah nilai dengan menggunakan ‘Bacterial Reverse Mutation Assay’ (ujian Ames). ‘Bacterial Reverse Mutation Assay’ 
untuk HA ini telah dilakukan ke atas Salmonella typhimurium strain TA98, TA100, TA1535, TA1537 dan Escherichia 
coli strain WP2 uvrA dengan menggunakan cara prainkubasi dengan kehadiran dan ketidakhadiran sistem pengaktifan 
metabolik eksogenus. Kesemua strain bakteria yang diuji, yang dirawat dengan atau tanpa ‘S9 Mix’ menunjukkan tiada 
pertambahan koloni ‘revertant’ dengan penambahan kepekatan bahan yang diuji untuk ujian pencarian dos dan ujian 
utama. Jumlah bilangan koloni ‘revertant’ adalah berkurangan dua kali ganda dengan kawalan pelarut untuk kesemua 
lima strain bakteria dan ini adalah sama untuk kedua-dua ujian pencarian dos dan ujian utama. Jumlah bilangan koloni 
‘revertant’ untuk kawalan negatif dan positif adalah dalam lingkungan data latar makmal. Kesimpulannya, keputusan 
daripada ujian-ujian menunjukkan HA tambah nilai ini telah dianggap tiada potensi mutagenik berbalik dalam keadaan 
yang diuji.
Kata kunci: Genotoksisiti; hidroksiapatit; ujian Ames 
INTRODUCTION
Ceramic for bone replacement is one of the most active 
areas of biomaterials research today. At least 40 to 50 
different ceramic materials are under evaluation as implant 
materials. These are divided into three categories: (1) 
inert, (2) reactive or bonding and (3) resorbable. Like an 
autologous cancellous bone graft or a coral template, the 
resorbable ceramic prosthesis serves as a scaffolding for 
new bone growth and is eventually replaced by living 
tissue. The advantage of the resorbable material is that there 
will be no long term stability or compatibility problems. 
The disadvantages are strength degradation during the 
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remodeling process, which may cause mechanical implant 
failure (Bajpai et al. 1976; Ferraro 1979).
 One of the active resorbable ceramic biomaterials 
research was on calcium phosphate mainly composed of 
hydroxyapatite. Virtually all current calcium phosphate 
biomaterials can be classified as polycrystalline ceramics 
since their material structure is derived from individual 
crystals of highly oxidized substance that have been 
fused together at the crystal grain boundaries by a high 
temperature process called sintering (Jarcho 1981; Meffert 
et al. 1985).
 Hydroxyapatite (HA) forms the principal mineral 
component of bone and comprises 60% to 70% of the 
calcified skeleton. Its chemical composition is Ca10( PO4)6 
(OH)2 and it has been produced synthetically since the 
early 1970s and used clinically for the last 20 years (Jarco 
1981). All forms of HA have excellent biocompatibility 
and when placed in contact with viable bone result 
in osseoconduction and osseointegration. There is no 
evidence that HA is osteogenic. HA does not cause chronic 
inflammatory response, toxic reactions or foreign body 
giant cell reactions (Constantino et al. 1991). 
 The principal limitation of calcium phosphate implant 
materials is their mechanical properties. Like most ceramics, 
these materials are quite brittle, have low impact resistance 
and relatively low tensile strengths (Jarcho  1981).
 The value added HA base material had been produced 
by a group of researchers at the School of Engineering, 
Universiti Sains Malaysia. The test substance was added 
with zirconia, to make it tougher. This value added HA 
which was stronger and easier to contour without breaking, 
was not too brittle. 
 This zirconia can retard the crack propagation by a 
kind of crack-closing mechanism, which will increase the 
toughness of the ceramics (Anderson 1990; Smith 1996). 
An extra element, zirconia has been added to increase the 
strength of HA structure. Some studies showed that zirconia 
had no cytotoxic effects when fibroblasts were co-cultured 
with it or with extracts using different methods (viability of 
cells and MTT assay) (Piconi and Maccauro 1999 ). On the 
other hand, Li et al. (1993) evaluated the biocompatibility 
of various ceramics powder including zirconia with human 
fibroblast cells in vitro study. In that study, cultured 
human fibroblast cells were exposed to different types of 
ceramic powders: zirconia (ZP), alumina (A), tricalcium 
phosphate (TCP) and hydroxyapatite (HA). The cells’ 
viability at different exposure times were measured by 
colony formation. A and HA showed no cytotoxic effects 
whereas ZP and TCP inhibited cells viability.
 To develop biocompatibility of the biomaterial which 
can be used as a bone replacement material, there are 
several studies that can be undertaken such as animal study, 
cytotoxicity testing as well as genotoxicity evaluation. 
The biomaterial used has to maintain its biocompatibility 
similar to that of the standard biomaterial that is already 
being used in clinical practice.
 Biocompatibility has undergone a change of emphasis 
in the past years and is now generally accepted as involving 
two principal areas. The first is the principle of ‘biosafety’, 
which involves the exclusion of severe deleterious effects 
of the biomaterial on the organism. This encompasses 
both cytotoxicity and the complicated field of mutagenesis 
and carcinogenesis. The second area is concerned with 
‘biofunctionality’, an aspect which deals with the ‘ability 
to perform with an appropriate host response in a specific 
application (William 1987). Although measures of a medical 
product’s biocompatibility have largely been reported 
in terms of irritation, sensitization and systemic toxicity, 
there is growing concern that devices, their components or 
material extracts may also exert genotoxic effects. Thus, 
any attempt to assess the safety of a device intended for 
intimate body contact or permanent implantation would 
be incomplete without testing for the presence of toxins 
that exert an effect on the genetic material of cells. In its 
set of harmonized standards for the biological evaluation 
of medical devices, the International Organization for 
Standardization (ISO) has outlined the need for such 
genotoxicity testing in ISO 10993-3: “Tests for Genotoxicity, 
Carcinogenicity and Reproductive Toxicity” (Johnson et 
al.1998). An international standard (ISO 10993) lays down 
specific requirements for biocompatibility, including the 
tests based on the nature of the contact and the duration of 
implantation of the biomaterial. The standard stipulates that 
all materials that will be in contact with mucous membrane, 
bone or dentinal tissue where the contact exceeds 30 days, 
as well as all implantable devices where the contact exceeds 
24 hours, must undergo genotoxicity testing (Chauvel-
Labret et al. 2001). Most tests included in this part of 
the International Standard refer to the Organization for 
Economic Cooperation and Development (OECD) Guidelines 
for testing of chemicals. Test methods shall normally be 
chosen from the OECD Guidelines for testing of chemicals: 
471- 485 (Chauvel-Lebret et al. 2001). Genotoxicity test 
can be defined as a test that applies mammalian or non-
mammalian cells, yeasts or fungi to determine whether gene 
mutations, changes in chromosome structure or other DNA 
or gene changes are caused by the test materials, devices 
and/or extracts from these materials (ISO 1992). When the 
genetic toxicity of a medical device has to be experimentally 
assessed, a series of in vitro tests can be used. This series 
shall include at least three assays. At least two of these should 
preferably use mammalian cells as a target. The tests should 
preferably cover the three levels of genotoxic effects: DNA 
effects, gene mutations and chromosomal aberrations (ISO 
1992). 
 The aim of this study was to determine this value 
added hydroxyapatite based material for its genotoxicity 
properties in vitro study by using Bacterial Reverse 
Mutation Assay (Ames test).
MATERIALS AND METHODS
TEST SUBSTANCE
The value added HA base material had been produced 
by a group of researchers at the School of Engineering, 
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Universiti Sains Malaysia and this genotoxicity study was 
done in SIRIM. This value added HA which is stronger and 
easier to contour without breaking, is not too brittle. The 
structural or rational formula is Ca10(PO4)6(OH)2. The test 
substance was HA with zirconia added to make it tougher. 
It was a whitish grey fine powder. The test substance was 
stored at room temperature. Aseptic precautions were taken 
when handling the test substance. 
NEGATIVE AND POSITIVE CONTROLS
The negative control used in this study was sterile distilled 
water. Specific positive controls were used in order to 
confirm the reversion properties and the specificity of each 
tester strain and the efficacy of the metabolic activation 
system. Toxic positive control application caused genotoxic 
effect (reverse mutation) to bacterial strains. Four types 
of positive controls were used and these include: 2-(2-
Furyl)-3-(5-nitro-2-furyl)acrylamide(AF-2), Sodium azide 




Salmonella typhimurium strains TA98, TA100, TA1535 
and TA 1537 and Escherichia coli strain WP2 uvrA were 
obtained from the National Institute of Health Science, 
Tokyo, Japan. S. typhimurium strains TA100, TA1535 
and E. coli strain WP2 uvrA were used for detection of 
base-pair substitution mutations, while S. typhimurium 
strains TA98 and TA1537 for the detection of frameshift 
mutations.
MEDIUM AND S9 MIx
Minimal glucose agar plate was supplied by Oriental Yeast 
Co. Ltd., Japan and consisted of following components: 
x20 Vogel-Bonner minimum medium E (50 ml/L), 40 
w/v % glucose (50ml/L) and Agar ( Bacto-Agar, Difco 
Laboratories) (15g/L). Soft agar containing 0.5 mM 
histidine and 0.5 mM biotin for S. typhimurium strains or 
0.5 mM tryptophan for E. coli strain was added to soft agar 
solution containing 0.6 w/v % agar (Bacto-Agar, Difco 
Laboratories) and 0.5 w/v % NaCl in a ratio of 1:10. S9 
Mix was supplied by Kikkoman Co. Ltd., Japan. One ml of 
S9 Mix contains protein (25.19 mg/ml), cytochrome P-450 
(0.97 nmol/mg protein), DMN demethylase activity (4.97 
nmol HCHO formed/mg protein/min ), aniline hydroxylase 
activity (24.02 nmol p-aminophenol formed/mg protein/
hr) and B [a] P hydroxylase activity (16.85 times higher 
than non induced S9). 
PRE-CULTURES
From the stock cultures, 36 µL of bacterial suspension was 
inoculated in a L-tube containing 18 mL nutrient broth 
No. 2 (Oxoid Ltd.), the bacterial culture was incubated 
at 37 ± 0.5°C for 6 to 9 hours with shaking at 57 times/
min in a Monod shaker (Figure 1). The viable cells count 
was calculated from the values which where determined 
at 660 nanometer by spectrophotometry at the end of 
incubation.
METHODS
The test was carried out for S. typhimurium TA98, TA100, 
TA1535, TA1537 and E. coli strain WP2 uvrA using the 
pre-incubation method both with and without metabolic 
activation system. Plating was done in triplicate for the 
negative control and in duplicate for the substance and 
positive controls. 
PROCEDURES
After 0.1 mL of the test substance solution, 0.5 mL of 
0.1 M sodium phosphate buffer (pH 7.4) or S9 Mix and 
0.1 mL of the bacterial culture were added to a tube, the 
mixture were incubated 20 min at 37 ± 0.5°C. 2 mL of 
soft agar was then added to each tube and poured onto a 
minimal glucose agar plate. After incubation for 48 h at 
37 ± 5°C, the number of revertant colonies was counted. 
As for the sterility test, 0.1 mL of test substance solution, 
S9 Mix and 0.1 M sodium phosphate buffer (pH 7.4) 
were poured onto a minimal glucose agar plate and 
incubated at 37 ± 0.5°C for 48 h to check for the bacterial 
contamination. Pure water was used as negative control 
and the following positive controls were used for each 
bacterial strains. 
DOSE FINDING TEST
The test was carried out at the highest dose of 5,000 μg/
plate and 4 doses of 2500, 1250, 625 and 313 μg/plate. 
Growth inhibition was not observed at any of these doses 
for all the bacterial strains tested both in the presence 
or absence of S9 Mix. Test plates of TA98, TA100, 
TA1535, TA1537 and WP2 uvrA with and without S9 
Mix showed no increase of revertant colonies for all the 
doses tested.











Dose finding test 1.00 1.12 1.06 1.06 1.02
Main test 1.07 1.00 1.40 1.09 1.03
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MAIN TEST
Based on the results of the dose finding test, a maximum 
dose was decided at 5000 µg/plate. The lower 4 doses 
were obtained by a dilution with a geometric progression 
of 2, i.e. replicating exactly the procedure carried out in 
the dose finding test.
MICROSCOPIC OBSERVATION
The state of the revertant colonies (size or number of 
colonies) and growth inhibition were examined with a 
stereo microscope. 
COLONY COUNTING
The number of colonies were counted with a manual 
counter or a colony analyzer (Protocol). Each plate was 
counted three times and the average of the three counts 
was adopted as the number of revertant colonies on the 
plate. The average number of revertant colonies for each 
dose was calculated as the average plate count for a set of 
duplicate. Decimals of the average figures were rounded 
off.
INTERPRETATION OF THE RESULTS
Signs of toxicity or growth inhibition for all the bacterial 
strains under the test condition was described in this report. 
The test substance was judged to be negative, when the 
number of revertant colonies was less than twice that of 
the negative control. 
ANALYSIS
Non statistical procedures   For this study, a non-statistical 
procedure was used to evaluate the results of Salmonella 
experiments (Mortelmans & Zeiger 2000).
• Positive: A compound is considered a mutagen if 
it produces a reproducible, dose-related increase 
in the number of revertant colonies in one or more 
strains. A minimum fold increase, usually 2–3 fold, 
in revertants (over the solvent control) is the cut-off 
between a mutagenic and nonmutagenic response. 
A compound is considered a weak mutagen if it 
produces a reproducible, dose-related increase in the 
number of revertant colonies in one or more strains 
but the number of revertants is not double of the 
background.
• Negative: A compound is considered a nonmutagen 
if no dose-related increase in the number of revertant 
colonies is observed in at least two independent 
experiments. 
• Inconclusive: If a compound cannot be identified 
clearly as a mutagen or a nonmutagen, the results are 
classified as inconclusive.
RESULTS
RESULTS OF PLATE COUNTS OF RANGE FINDING TESTS
In the preliminary experiment, the test substance was carried 
out at the highest dose of 5,000 µg/plate for detection of 
cytotoxicity. Growth inhibition was not observed and 
TABLE 2. Positive controls of bacterial strains
TA100 TA1535 WP2 uvrA TA98 TA1537




















FIGURE 1. Overview of bacterial reverse mutation test 
(Ames Test) Process
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test plate showed no increase of revertant colonies. The 
test substance was tested at different concentrations of 
313 µg/plate, 625 µg/plate, 1250 µg/plate, 2500 µg/
plate and 5000 µg/plate. For the test substance, negative 
control and positive controls tests were performed on 
Salmonella typhimurium strains TA98, TA100, TA1535, 
TA1537 and Escherichia coli strain WP2 uvrA using the 
preincubation method in the presence and absence of an 
exogenous metabolic activation system. The test substance 
was judged to be negative, when the number of revertant 
colonies was less than twice that of the negative control. 
The results of plate counts for the range finding tests were 
shown in Figures 2 and 3. No dose-response relationship 
and reproducibility was obtained. No statistical procedure 
was used.
RESULTS OF PLATE COUNT OF MAIN TESTS
Based on the results of the range finding tests, a maximum 
dose was decided at 5000 µg/plate. The test substance was 
tested at different concentrations of 313 µg/plate, 625 µg/
plate, 1250 µg/plate, 2500 µg/plate and 5000 µg/plate. For 
the test substance, negative control and positive controls 
tests were performed on Salmonella typhimurium strains 
FIGURE 2. Four strains of S. typhimurium and one strain of E. coli were devoid 
of cytotoxicity in the Ames test without metabolic activation (-S9)
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TA98, TA100, TA1535, TA1537 and Escherichia coli strain 
WP2 uvrA using the preincubation method in the presence 
and absence of an exogenous metabolic activation system. 
The test substance was judged to be negative, when the 
number of revertant colonies was less than twice that of the 
negative control. The results of plate counts for the main 
tests were shown in Figures 4 and 5. No dose-response 





Before new materials are approved for medical use, 
mutagenesis systems to exclude cytotoxic, mutagenic or 
carcinogenic properties are applied worldwide. Although 
indispensable within the framework of in vitro evaluation, 
these screening procedures are usually very work-intensive 
and time-consuming. They must be carried out for the 
raw material as well as the manufactured implant in 
order to exclude the possibility that the properties of the 
FIGURE 3. Four strains of S. typhimurium and one strain of E. coli were devoid 
of cytotoxicity in the Ames test with metabolic activation (+S9)
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material are influenced by the industrial manufacturing 
process (Katzer et al. 2002). To reduce the number of 
biomechanical studies, evaluation of new biomaterials 
should nowadays begin with in vitro cytotoxicity and 
mutagenicity tests. This applies for the development of 
both temporary and permanent implants and prostheses 
and for permanent implant particularly under the aspect 
that carcinogenic potential is often the consequence of 
chronic exposure to minute concentrations (Katzer et 
al. 2002). This test is commonly employed as an initial 
screen for genotoxic activity and in particular, for point 
mutation-inducing activity. An extensive data base has 
demonstrated that many chemicals that are positive in this 
test also exhibit mutagenic activity in other tests. There are 
examples of mutagenic agents which are not detected by 
this test; reason for these shortcomings can be ascribed to 
the specific nature of the endpoint detected, differences in 
metabolic activation or differences in bioavailability. On 
the other hand, factors which enhance the sensitivity of the 
bacterial reverse mutation test can lead to overestimation 
FIGURE 4. The test for mutagenesis in five strains without metabolic activation (-S9) 
with different concentrations of HA, gave no evidence for mutagenic effects
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of mutagenic activity (OECD 1997). In this study, all the 
bacterial tester strains treated with and without S9 Mix 
showed no increase of revertant colonies with increase in 
concentration of test substance for both the range finding 
test and the main test. The number of revertant colonies 
was less than twice that of the solvent control for all the 
five bacterial strains and this was reproducible for both the 
dose finding test and the main test. Positive results from 
the bacterial reverse mutation test indicate the substance 
induces point mutations by base substitutions or frameshifts 
in the genome of either Salmonella typhimurium and/or 
Escherichia coli. Negative results indicate that under the 
test conditions, the test substance is not mutagenic in the 
tested species. Although all known assays can yield false-
positive and false-negative results, experience shows that 
the combination of two different test methods is a reliable 
parameter for determining carcinogens which are a risk to 
human health (Katzer et al. 2002)
FIGURE 5. The test for mutagenesis in five strains with metabolic activation (+S9) 
with different concentrations of HA, gave no evidence for mutagenic effects
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CONCLUSION
 The present in vitro evaluation indicated that the value 
added HA was not genotoxic. The genotoxic effect was 
absent at different concentrations of 313 µg/plate, 625 
µg/plate, 1250 µg/plate, 2500 µg/plate and 5000 µg/plate 
for all the bacterial tester strains treated with and without 
S9 Mix. No dose-response relationship was obtained in 
this study for HA. 
 In conclusion, the results of the tests conducted in this 
research showed that the value added HA was considered to 
have no reverse mutagenic potential and is a biocompatible 
biomaterial under the present test conditions. This bone 
replacement material is now being widely used in Dentistry 
and Orthopedic surgery in Malaysia and in other countries 
because of its biocompatibility with human tissue and cost 
effectiveness. 
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